Actualités sur Health

23.04.2013 – 12:37
Bristol-Myers Squibb GmbH & Co. KGaA
High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection
Princeton, New Jersey (ots/PRNewswire) - - This all-oral treatment regimen is being studied as an interferon-free and ribavirin-free option - Investigational regimen involves three different classes of direct-acting antivirals (DAAs) - an NS5A replication complex inhibitor, an NS3 protease inhibitor and an NS5B ...
plus
23.04.2013 – 01:02
The European Brain Council, Global Alliance of Mental Illness Advocacy Networks-Europe and Shire AG
New Expert White Paper Recommends Framework for Action to Tackle Impact of ADHD on Individuals, Families and Society
Brussels (ots/PRNewswire) - A new Expert White Paper, ADHD: Making the Invisible Visible, was today presented to policymakers and key stakeholders by a multidisciplinary group of experts. This Expert White Paper project was initiated, facilitated and funded by Shire AG and supported by the European Brain Council ...
plus
22.04.2013 – 12:57
ViroPharma Incorporated
News Alert: ViroPharma reinforces commitment to address medical needs and provide innovative treatment options for patients with adrenal insufficiency at ECE
Maidenhead, England (ots/PRNewswire) - Who: ViroPharma, an international biopharmaceutical company committed to developing and commercialising innovative solutions for physicians to address the unmet medical needs of patients living with diseases that have few, if any, clinical therapeutic options. What: European ...
plus
22.04.2013 – 07:31
Sanofi Pasteur MSD GmbH
Hexyon[TM] 6-in-1 Paediatric Vaccine Approved in Europe
Lyon, France (ots/PRNewswire) - Hexyon is Europe's only fully liquid, ready-to-use hexavalent paediatric vaccine Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur in Europe, announced today that the European Commission has granted a community marketing authorisation for Hexyon[TM], an innovative new 6-in-1 paediatric vaccine. Hexyon[TM] is the only fully liquid, ready-to-use 6-in-1 vaccine to protect ...
plus
19.04.2013 – 13:32
Aspect Imaging
Aspect Imaging Announces FDA Clearance of M2(TM) Compact MRI System for Clinical Imaging of the Wrist
Salt Lake City (ots/PRNewswire) - - Clinical studies on point-of-care wrist imaging planned at UCLA - Using this novel compact MRI platform Aspect Imaging, the world leading developer of compact high-performance magnets, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's ...
plus
18.04.2013 – 17:36
LifeWatch AG
EANS-Adhoc: LifeWatch AG publishes Annual Report 2012 (with document)
http://resources.euroadhoc.com/us/ZP1fI8rj issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard: ...
Un document
plus

18.04.2013 – 13:02
Resverlogix Corp.
Resverlogix Completes Dosing in ASSURE Clinical Trial
Calgary, Alberta (ots/PRNewswire) - IVUS data will evaluate plaque regression in patients with high-risk Cardiovascular Disease TSX Exchange Symbol: RVX Resverlogix Corp. today announced that it has completed dosing in ASSURE, a Phase 2b clinical trial evaluating RVX-208, Resverlogix's first-in-class orally active BET-protein inhibitor, using intra-vascular ultrasound (IVUS) in high-risk cardiovascular patients with low ...
plus
18.04.2013 – 12:58
UBM Live
CPhI South East Asia Indicates Rapid Pharma Sector Growth for the ASEAN
Amsterdam (ots/PRNewswire) - Record numbers, a focus on development initiatives and analysis of the regional harmonisation programme helps stimulate increased partnerships CPhI, a division of UBM Live, announces that this year's recent CPhI South East Asia 2013, which ran from 20-22nd March at the Jakarta International Expo in Indonesia, was the most successful so far. ...
plus
18.04.2013 – 09:02
Pronota
Better Diagnosis of Acute Heart Failure Using Pronota's Novel Biomarker
Ghent, Belgium (ots/PRNewswire) - Two independent validation studies demonstrate that Pronota's biomarker CD146 significantly improves the diagnosis of acute heart failure for patients with shortness of breath. The biomarker, measured in blood, provides clinicians with unique additional information allowing better treatment of this challenging group of patients. ...
plus
17.04.2013 – 09:00
The International Osteoporosis Foundation (IOF)
New data reveal increasing burden of osteoporosis in Europe
Rome, Italy (ots) - Every year 43,000 people die following osteoporotic fractures; reports show that European healthcare systems are not treating people at risk; burden and costs will rise dramatically by 2025. Two landmark multi-stakeholder reports launched today - Osteoporosis in the European Union and the Scorecard for Osteoporosis in Europe - describe and compare the epidemiology, burden, and management of ...
plus
16.04.2013 – 07:02
Sanofi Diabetes
Sanofi Announces Call for Submissions for Ignite: The Diabetes Ideas Challenge
Paris (ots/PRNewswire) - - Worldwide invitation to create and submit concepts for a potential next-generation insulin delivery device - Sanofi announced today that it is accepting submissions for Ignite: The Diabetes Ideas Challenge ("Ignite Challenge"). The web-based Ignite Challenge invites patients, caregivers, designers, engineers, and innovators from around the ...
plus
11.04.2013 – 08:54
Sanofi Pasteur MSD GmbH
Sanofi Pasteur MSD Submits Quadrivalent Influenza Vaccine for European Licences
Lyon, France (ots/PRNewswire) - - Addition of fourth influenza virus strain aims to increase protection against influenza - Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, announced today that it has submitted a decentralized marketing authorization application in Europe for a 'Quadrivalent' influenza vaccine, a new advanced seasonal flu vaccine. ...
plus

09.04.2013 – 20:00
Duchesnay inc.
The Canadian Pharmaceutical Company Duchesnay Inc. Sets for International Expansion Following the US Approval of its Morning Sickness Medication Diclegis® by the FDA
Blainville, Canada (ots/PRNewswire) - Following the US approval of its morning sickness medication Diclegis by the US Food and Drug Administration (FDA) [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm347087.htm ], the Canadian pharmaceutical company Duchesnay Inc. ...
plus
08.04.2013 – 13:01
Resverlogix Corp.
Resverlogix to Spin-out RVX Therapeutics Inc. to Shareholders
Calgary, Canada (ots/PRNewswire) - Transaction Designed to Enhance Shareholder Value By Unlocking Value of the Epigenetics Platform TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix") today announced that its Board of Directors has approved a proposal to spin-out its subsidiary, RVX Therapeutics Inc. ("RVX Therapeutics"), which will focus on innovative drug research and development by leveraging its epigenetics ...
plus
02.04.2013 – 17:36
LifeWatch AG
EANS-Adhoc: LifeWatch confirms receipt of a request from a shareholder group to include additional motions in the agenda of the AGM (with document)
http://resources.euroadhoc.com/us/YgQnBzd2 issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
Un document
plus
02.04.2013 – 06:02
Eisai Europe Limited
Inovelon®(rufinamide) Oral Suspension Formulation Launched in France
Hatfield, England (ots/PRNewswire) - Child friendly formulation will help treatment of orphan syndrome LGS a severe form of childhood epilepsy Inovelon(R) (rufinamide) oral suspension for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years and older is launched today in France. The new formulation of the orphan ...
plus
27.03.2013 – 17:21
Evaluate Ltd.
Pharma in 2012: Boom or Bust?
London And Boston (ots/PRNewswire) - EP Vantage(R) [http://www.epvantage.com/default.aspx ], EvaluatePharma(R) [http://www.evaluatepharma.com ]'s award-winning editorial team, today released its "2012 Year in Review [http://www.evaluatepharma.com/epvreview2012 ]" report. Despite numerous ups and downs, the sector exited on a positive note, giving hope that 2013 might be the start of sustained recovery. According to the report, Biotech stocks stormed ahead with the NASDAQ ...
plus
25.03.2013 – 17:37
LifeWatch AG
EANS-Adhoc: LifeWatch AG: Kenneth Melani designated as new Chairman. Yacov Geva will continue to act as the Corporate CEO. (with document)
http://resources.euroadhoc.com/us/jG8iMykS issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
Un document
plus

25.03.2013 – 13:15
Shire Pharmaceuticals Group Plc
Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
Lexington, Massachusetts (ots/PRNewswire) - Acquisition brings Shire a new phase 3 compound being investigated for the signs and symptoms of Dry Eye Disease Shire plc today announced that it will acquire SARcode Bioscience Inc., a privately held biopharmaceutical company based in Brisbane, California. This acquisition continues to build Shire's presence in the ...
plus
21.03.2013 – 10:03
Takeda Pharmaceuticals Europe Ltd
Takeda Launches New Subsidiary in Ecuador
Zurich, Switzerland (ots/PRNewswire) - Demonstrates Takeda's long-term commitment to the Latin American market Takeda Pharmaceuticals International GmbH ("Takeda"), today announced further expansion of its presence in Latin America with the launch of its wholly-owned subsidiary in Ecuador. Takeda Ecuador S.A. (Takeda Ecuador or "the Company") will be headquartered in Quito and will be responsible for the sales and ...
plus
21.03.2013 – 00:23
LEO Pharma
Article Published in JAMA Dermatology Shows Long-term Effectiveness of Ingenol Mebutate in Treating Actinic Keratosis
Ballerup, Denmark (ots/PRNewswire) - Two-three day treatment provides clinically relevant, sustained clearance of AK after 12 months An analysis of long-term clearance rates of actinic keratosis (AK) lesions after treatment with ingenol mebutate (Picato(R)) gel is today published in the Journal of the American ...
plus
20.03.2013 – 15:08
European Crop Protection Association
ECPA Welcomes EFSA's Scientific Input but sees it as Late and Fears ED Rules will Crush Innovation in Farm Inputs
Brussels (ots/PRNewswire) - Today the European Food Safety Authority's (EFSA) Scientific Committee published its opinion on identifying endocrine disrupting chemicals (EDs). ECPA welcomed the EFSA opinion but is concerned how late the input has been requested in a process that has been rushed to meet political ...
plus
18.03.2013 – 13:03
Virobay, Inc. and LEO Pharma A/S
Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
Menlo Park, California And Ballerup, Denmark (ots/PRNewswire) - Virobay, Inc. and LEO Pharma A/S today announced that their collaboration on the development of an oral treatment for psoriasis has reached an important milestone as Virobay has now initiated a Phase 1 clinical trial of VBY-891 - a selective cathepsin S ...
plus
18.03.2013 – 09:03
Astellas European Foundation
Astellas European Foundation Announces Winner of the Functional Urology and Uro-Gynaecology Grant
Milan (ots/PRNewswire) - Dr Pieter Groenendijk Wins $150,000 Grant to Support his Research in Understanding Urethral Pressure Variations During Filling Cystometry The Astellas European Foundation is pleased to announce Dr Pieter Groenendijk as the winner of the $150,000 Functional Urology and Uro-Gynaecology Grant. Dr Groenendijk, a urologist from Medisch Centrum ...
plus

15.03.2013 – 17:22
European Crop Protection Association
European Crop Protection: Failure to Reach Consensus on Important Pesticides in EU Committee Vote
Brussels (ots/PRNewswire) - ECPA recommends proportionate, evidence-based approach, as Standing Committee delivers 'no opinion' on neonicotinoids Member States have failed to reach a qualified majority in a vote potentially leading to a ban on the use of neonicotinoid based pesticides on crops attractive to bees. The European Commission's Appeal Committee will now ...
plus
14.03.2013 – 12:03
FC Barcelona and The European Commission
Sixty Thousand Europeans 'Quit Smoking With Barça' and the European Commission
Brussels (ots/PRNewswire) - Today, an important benchmark of more than 60,000 smokers across Europe has been reached with the innovative smoking cessation programme, 'Quit Smoking With Barça' (http://www.quitsmokingwithbarca.eu). This programme is a collaborative effort between FC Barcelona (FCB) and the European Commission. This notable achievement comes less than ...
plus
14.03.2013 – 10:48
Astellas Pharma Europe Limited
European Commission Approves New Pre-treatment Options for QUTENZA(TM) (8% Capsaicin Patch) in Peripheral Neuropathic Pain
Chertsey, England (ots/PRNewswire) - - For Healthcare and Business Media - Approval allows for more flexible approach to 8% capsaicin patch treatment of peripheralneuropathic pain The European Commission (EC) has approved expanded options for pre-treatment prior to use of QUTENZA (8% capsaicin patch). Before ...
plus
12.03.2013 – 13:03
Shire Pharmaceuticals Group Plc
Shire Acquires Premacure AB
Lexington, Massachusetts (ots/PRNewswire) - Deal Enhances Shire's Late-Stage Pipeline with the Acquisition of a Phase II Protein Replacement Therapy Being Investigated for the Prevention of Retinopathy of Prematurity Shire plc announces that it has acquired Premacure AB of Uppsala, Sweden, a privately held biotechnology company developing a protein replacement therapy, currently in Phase II development, for the prevention of retinopathy of prematurity (ROP). ROP is a rare ...
plus
11.03.2013 – 13:02
SIU-Societe Internationale d'Urologie
The Société Internationale d'Urologie Launches SIU Academy, A Powerful New Resource for Urologists
Montreal (ots/PRNewswire) - The Société Internationale d'Urologie is pleased to announce the launch of SIU Academy [http://www.siu-academy.org ], a powerful new eLearning resource for urologists. Engineered for the cloud, SIU Academy [http://www.siu-academy.org ] can be accessed anywhere in the world. All users ...
plus
07.03.2013 – 21:27
Eisai Europe Limited
Eisai Appalled by the German Federal Joint Committee's Decision on Innovative Antiepileptic Drug Fycompa® (perampanel)
Frankfurt, Germany And Hatfield, England (ots/PRNewswire) - The German Federal Joint Committee (G-BA), the decision-making body of the self-governing medical system in Germany, today announced that it considers the additional benefit of Fycompa(R) (perampanel) unproven when compared to two other treatments as ...
plus

Précédent50515253545556575859Suivant